Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3102 - Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors


10 Oct 2016


Poster display


Beatrice Savastano


Annals of Oncology (2016) 27 (6): 1-14. 10.1093/annonc/mdw362


B. Savastano, C.M. Della Corte, F. Papaccio, V. Giuseppe, G. Esposito, M. Fasano, M. Orditura, F. De Vita, F. Ciardiello, F. Morgillo

Author affiliations

  • Medicina Clinica Sperimentale Magrassi Lanzara, AOU Seconda Università degli Studi di Napoli (AOU-SUN), 80131 - Napoli/IT


Abstract 3102


Resistance to first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) is mainly mediated by the acquisition of the EGFR secondary mutation T790M and/or by the acquisition of a mesenchymal phenotype. We explored the occurrence of epithelial to mesenchymal transition (EMT) characteristics in EGFR-TKIs resistant NSCLC models, with and without acquisition of T790M mutation, and the ability of novel generation EGFR inhibitors to revert the resistant phenotype.


The following human NSCLC cell lines harboring EGFR activating mutations were used: HCC827 and PC9 NSCLC cell lines harboring EGFR activating mutation (del 746-750), the PC9-T790M (T790M+) and the HCC827-GR (T790M-) gefitinib resistant cells, and the H1975 carrying both EGFR activating and T790M mutations. The mesenchymal behavior and the effects of afatinib and osimertinib on resistant cell lines were studied both in vitro, by Western blot analysis, invasion, migration and anchorage-independent growth assays and in vivo, by metastatic assay in mice after tail vein injection with resistant cells.


All gefitinib resistant cell lines, H1975, HCC827GR and PC9-T790M, exhibited significant higher protein expression of mesenchymal proteins, such as vimentin, Slug and VE-Cadherin and lost of E-Cadherin, as compared to gefitinib sensitive cells, with increased ability to migrate, invade and grow in anchorage-independent manner. Treatment with afatinib, and, to a greater extent, with osimertinib, strongly inhibited proliferation, migration, invasion and anchorage independent colon forming ability of H1975 and PC9-T790M cells, while effects were similar on HCC827-GR cells in vitro. Metastasic assay in vivo confirmed the superiority of osimertinib in T790M+ models


Collectively, these results suggest that EGFR mutant NSCLC cells resistant to first generation EGFR-TKI develop a mesenchymal phenotype, independently from the acquisition of T790M mutation. In this scenario, osimertinib is the most potent agent to overcome resistance and to revert the metastatic behavior of resistant cells.

Clinical trial identification

Legal entity responsible for the study

Second University of Naples


Second University of Naples


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings